Literature DB >> 8659489

Estimability and interpretation of vaccine efficacy using frailty mixing models.

M E Halloran1, I M Longini, C J Struchiner.   

Abstract

The authors consider estimability and interpretation of vaccine efficacy based on time to event data, allowing that some of the population might have a very low probability of acquiring disease, and the rest have partial, possibly continuously distributed, susceptibility. The efficacy parameters of interest in the frailty mixing model include the fraction highly unlikely to acquire the infection or disease due to the vaccine, the degree of partial protection in those still susceptible, and the average protection or summary measure of efficacy under heterogeneity. The efficacy estimates can still be usefully interpreted when the heterogeneity results from heterogeneity in contact patterns, contact rates, or infectiousness of the contacts, as long as these are equal in the vaccinated and unvaccinated groups. A likelihood-based method allows estimation of the efficacy parameters of interest from grouped time to event data. Simulated vaccine studies assuming different levels and distributions of efficacy demonstrate that ignoring heterogeneity in susceptibility or exposure to infection generally results in underestimation of vaccine efficacy as well as incorrect interpretation of the estimates. The approach is also applicable to other covariates affecting susceptibility or exposure to infection in infectious diseases. Exploitation of the dependent happening structure of infectious diseases to obtain a shape for the baseline hazard may help identifiability. The authors recommend fitting several models to time to event data in vaccine studies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8659489     DOI: 10.1093/oxfordjournals.aje.a008858

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  29 in total

1.  Randomization and baseline transmission in vaccine field trials.

Authors:  C J Struchiner; M E Halloran
Journal:  Epidemiol Infect       Date:  2007-02       Impact factor: 2.451

2.  A quantitative test of the relationship between parasite dose and infection probability across different host-parasite combinations.

Authors:  Frida Ben-Ami; Roland R Regoes; Dieter Ebert
Journal:  Proc Biol Sci       Date:  2008-04-07       Impact factor: 5.349

3.  Measurement of Vaccine Direct Effects Under the Test-Negative Design.

Authors:  Joseph A Lewnard; Christine Tedijanto; Benjamin J Cowling; Marc Lipsitch
Journal:  Am J Epidemiol       Date:  2018-12-01       Impact factor: 4.897

4.  Transmission dynamics of Ebola virus disease and intervention effectiveness in Sierra Leone.

Authors:  Li-Qun Fang; Yang Yang; Jia-Fu Jiang; Hong-Wu Yao; David Kargbo; Xin-Lou Li; Bao-Gui Jiang; Brima Kargbo; Yi-Gang Tong; Ya-Wei Wang; Kun Liu; Abdul Kamara; Foday Dafae; Alex Kanu; Rui-Ruo Jiang; Ye Sun; Ruo-Xi Sun; Wan-Jun Chen; Mai-Juan Ma; Natalie E Dean; Harold Thomas; Ira M Longini; M Elizabeth Halloran; Wu-Chun Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-28       Impact factor: 11.205

Review 5.  Temporally Varying Relative Risks for Infectious Diseases: Implications for Infectious Disease Control.

Authors:  Edward Goldstein; Virginia E Pitzer; Justin J O'Hagan; Marc Lipsitch
Journal:  Epidemiology       Date:  2017-01       Impact factor: 4.822

6.  Apparent declining efficacy in randomized trials: examples of the Thai RV144 HIV vaccine and South African CAPRISA 004 microbicide trials.

Authors:  Justin J O'Hagan; Miguel A Hernán; Rochelle P Walensky; Marc Lipsitch
Journal:  AIDS       Date:  2012-01-14       Impact factor: 4.177

7.  Displacement of sexual partnerships in trials of sexual behavior interventions: A model-based assessment of consequences.

Authors:  Alethea W McCormick; Nadia N Abuelezam; Thomas Fussell; George R Seage; Marc Lipsitch
Journal:  Epidemics       Date:  2017-04-02       Impact factor: 4.396

8.  Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials.

Authors:  Michael T White; Jamie T Griffin; Chris J Drakeley; Azra C Ghani
Journal:  Malar J       Date:  2010-03-23       Impact factor: 2.979

9.  Impact of stochastically generated heterogeneity in hazard rates on individually randomized vaccine efficacy trials.

Authors:  Rebecca Kahn; Matt Hitchings; Steven Bellan; Marc Lipsitch
Journal:  Clin Trials       Date:  2018-01-27       Impact factor: 2.486

10.  The potential epidemiological impact of a genital herpes vaccine for women.

Authors:  G P Garnett; G Dubin; M Slaoui; T Darcis
Journal:  Sex Transm Infect       Date:  2004-02       Impact factor: 3.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.